Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Therapeutic Hypothermia and Temperature Management
Instructions for Authors
W. Dalton Dietrich, III, PhD
Scientific Director, The Miami Project to Cure Paralysis
Kinetic Concepts Distinguished Chair in Neurosurgery
Professor of Neurological Surgery, Neurology and
Cell Biology and Anatomy
The Miami Project to Cure Paralysis
University of Miami
1095 NW 14th Terrace, Suite 2-30
Miami, FL 33136-1060
Telephone: (305) 243-2297
Fax: (305) 243-3207
AIMS and SCOPES:
Therapeutic Hypothermia and Temperature Management is a peer-reviewed journal covering all aspects of hypothermia and temperature considerations relevant to this exciting field. Novel findings from translational preclinical investigations as well as clinical studies and trials will be featured. The journal publishes original articles, state-of-the-art review articles, protocols and best practices.
Manuscripts must be submitted online using the following URL:
Please read all the instructions to authors before submitting.
Language must conform to acceptable English usage and syntax. The contents must be clear, accurate, coherent, and logical. In accepting or rejecting a manuscript, the editors will also consider its originality, teaching value, and validity.
Manuscripts should not exceed approximately 4,000 words. To facilitate a quick review of manuscripts, authors are encouraged to suggest names of five potential reviewers with complete contact information when the manuscript is submitted.
PUBLICATION ETHICS AND MALPRACTICE STATEMENT
Study Design and Ethics
Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.
Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.
Definitions of Scientific Misconduct
Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).
Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:
- Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
Material failure to comply with legislative and regulatory requirements affecting research:
Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
- Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
- Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
- Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.
Responding to Allegations of Possible Misconduct
The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
All allegations will be kept confidential.
For technical information on using Manuscript Central, contact Patricia Meravy at (914) 740-2132 or PMeravy@liebertpub.com
Manuscript Submission and Review
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted. By submitting a paper to the Journal, the author (or authors) agrees to each of the above conditions. In addition, the author (or authors) explicitly assigns any copyrighted ownership he/she (or they) may have in such paper to the Journal.
Preparation of Manuscripts
Papers must be submitted via upload in a word processing format, preferably in Microsoft Word. Please do not include artwork within the text document. Figures should be supplied in separate files, be labeled clearly, and should be in TIFF or EPS formats. Tables should be supplied in a separate Word file, and each table requires a title. Please see the Illustrations section for further details on art submission.
All copy must be double-spaced, including text, footnotes, references, legends, and tables. Text references must be supplied in sequence for all tables and figures. The title page should carry the full paper title, followed by the authors’ names, degrees, and where the work was performed. Please indicate the corresponding author.
An abstract should accompany every original paper. The abstract should appear on a separate page and should be at least 150 but not more than 300 words long. It should consist of factual information and not generalities (the problem investigated, the method used, the results obtained, and the conclusions reached). A brief introduction, materials and methods, results, discussion, acknowledgments, and reference sections should follow. At the conclusion of the references, the name and complete address of the reprint author should appear.
Correspondence and brief communications are published at the discretion of the editors as space permits. They should be double-spaced, and must not exceed 500 words in length.
The references must be double-spaced and must be cited in alphabetical order (by author), not numerical order. In-text citations should be in name, date format, and in parentheses.) The author is responsible for the accuracy and completeness of the references.
Povlishock JT, Wei EP. Posthypothermic Rewarming Considerations following traumatic brain injury. J Neurotrauma 2009;26:333–340.
[In-text citation sample: (Povlishock, 2009).]
**Abbreviate journal names according to the style of Medline.
Chapter in a Book:
Yenari MA, Wijman CAC, Steinberg, GK Effects of Hypothermia on Cerebral Metabolism, Bloodflow, and Autoregulation. In: Therapuetic Hypothermia. Mayer SA, Sessler DI (eds). New York, NY: Informa Healthcare . 2004: pp. 141-178.
[In-text citation sample: (Yenari, 2004).]
Tisherman S, Sterz FH. Therapeutic Hypothermia. New YorkNY: Springer. 2005.
[In-text citation sample: (Tisherman, 2005).]
If a statistical analysis is done, an explanation of how it was performed must be stated at the end of the section preceding results. Unusual or complex methods of analysis should be referenced.
Please follow these guidelines for submitting figures:
- Do NOT embed art files into a Word or PDF document. Figures provided in this format cannot be used for production purposes.
- Line illustrations should be submitted at 600 dpi.
- Halftones and color should be submitted at a minimum of 300 dpi.
- Save as either TIFF or EPS files. JPEG files are for screen representation-quality only and will print very poorly during the printing process. To ensure proper print quality, please submit only TIFF or EPS files.
- Color art must be saved as CYMK—not RGB. (NB: If files are submitted, the files will be converted to CYMK and some color variation will occur.)
- Black and white art must be submitted as grayscale—not RGB.
- Do NOT submit PowerPoint, PDF, Bitmap, or Excel figure or table files.
- When naming your figure and table files, please label them with the main author’s last name, followed by a period (.), and then list the figure number. Ex: Smith.Fig1; Smith.Table1.
Additional Information about Converting Figure Files:
Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:
- All files should be scanned at 100% size
- 300 dpi
- Final color mode: CMYK
- Save file as: .TIFor .EPS
If you need directions on how to convert a PowerPoint slide to acceptable format go to: www.liebertpub.com/MEDIA/pdf/ppconvert.pdf
Please upload individual files of all manuscript material—do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
Illustrations taken from other publications must be acknowledged by a complete credit line in the legend. The publisher’s letter of permission should be submitted to Therapeutic Hypothermia and Temperature Management.
Immediately following the Acknowledgments section, include a section entitled ‘‘Author Disclosure Statement.’’ This text must be part of your actual manuscript file. In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals at www.icmje.org/roles_e.html for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’
An e-mail containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned promptly to the publisher with the author’s approval and/or corrections.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215, Tel: (914) 740-2100; Fax: (914) 740-2101; E-mail: firstname.lastname@example.org; Website: www.liebertpub.com.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email email@example.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email firstname.lastname@example.org or visit Liebert Open Access for more information.